EMA Authorised: Nivestim (filgrastim) — Pfizer Europe MA EEIG

View source ↗

Summary

Nivestim (filgrastim) has been authorised by EMA for hematopoietic stem cell transplantation and cancer indications.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cancer
• Hematopoietic Stem Cell Transplantation

Drugs mentioned

• Nivestim (filgrastim)

Snippet

Status: Authorised. Therapeutic area: Hematopoietic Stem Cell Transplantation;Cancer. MAH: Pfizer Europe MA EEIG. Decision date: 18/08/2026